FDA told Anabolic Laboratories its CoQ10 Ubiquinol Prime and Policosanol Microtabs supplements were unapproved new drugs because website claims promised disease treatment.
What happened
In August 2022, FDA reviewed Anabolic Laboratories' website and determined that the company takes orders there for CoQ10 Ubiquinol Prime and Policosanol Microtabs. FDA found website claims that the products are intended to treat diseases and conditions such as heart failure and high cholesterol. FDA says those claims make the products drugs, and that they are unapproved new drugs and misbranded.
What FDA found
FDA says the website claims make CoQ10 Ubiquinol Prime and Policosanol Microtabs intended to cure, mitigate, treat, or prevent disease, so they are drugs under the Act.
Section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]FDA says these products are not generally recognized as safe and effective for those uses, making them unapproved new drugs.
Section 201(p) [21 U.S.C. 321(p)]FDA says a new drug cannot be introduced into interstate commerce without prior FDA approval.
Sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]FDA says CoQ10 Ubiquinol Prime is misbranded because it lacks adequate directions for use by a layperson.
Section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5FDA says introducing the misbranded drug into interstate commerce violates the Act.
Section 301(a) [21 U.S.C. 331(a)]
What FDA wants
Within 15 working days of receipt, FDA asks Anabolic Laboratories to notify it in writing of the specific steps taken to address the matters and prevent recurrence, with related documentation. If corrections cannot be completed in that time, FDA asks the company to explain the delay and state when corrections will be completed.
Who should pay attention
- dietary supplement brands making disease-treatment claims online
- contract manufacturers or distributors of CoQ10 and policosanol products
- regulatory reviewers of supplement websites and label claims
This is a summary. Read the original letter on fda.gov.